Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06153667 · ClinicalTrials.gov registry record
Bearing nsPVA Embolization for Uterine Artery Embolization (BETTER-UAE)
A clinical trial, sponsored by Merit Medical Systems.
- Recruiting
- Registry status
- 100
- Enrollment target
NCT06153667: Recruiting study, sponsored by Merit Medical Systems.
NCT06153667 is a clinical trial that is actively recruiting participants, run by Merit Medical Systems. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06153667 is actively recruiting participants, sponsored by Merit Medical Systems.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
Study Summary
This is a prospective, multicenter, observational, post-market clinical follow-up study in subjects treated with Bearing nsPVA Embolization Particles for uterine fibroid embolization. Data collection will include safety and performance outcome relating to the use of Bearing nsPVA, through 6 months.
Primary Outcome
The primary safety endpoint will be the absence of serious device-related adverse events (AEs) through 30 days.
Interventions
- DEVICE Bearing nsPVA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-08-22 |
| Est. Completion | 2026-12 |
What NCT06153667 shows while recruiting
NCT06153667 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Bearing nsPVA is the first listed.
NCT06153667 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06153667 about?
NCT06153667 is a clinical study titled "Bearing nsPVA Embolization for Uterine Artery Embolization (BETTER-UAE)". This is a prospective, multicenter, observational, post-market clinical follow-up study in subjects treated with Bearing nsPVA Embolization Particles for uterine fibroid embolization. Data collection will include safety and performance outcome relating to the use of Bearing nsPVA, through 6 months.
What is the current status of trial NCT06153667?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2024-08-22. Estimated completion is 2026-12.
What interventions are being tested in trial NCT06153667?
The interventions under investigation include: Bearing nsPVA (DEVICE).
Who is sponsoring clinical trial NCT06153667?
This trial is sponsored by Merit Medical Systems, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI